Strides Optimistic On Prospects Of Antiviral Portfolio For COVID-19
Favipiravir Bioequivalence Studies To Begin In India
Optimistic about the potential of repurposing its antiviral portfolio, Strides plans to soon begin bioequivalence studies for favipiravir, a molecule that has found favor as a COVID-19 therapy in a few countries. It also aims to introduce new products to fill the gap left by the withdrawal of ranitidine from the US market.
